Norwegian biotech concludes 'strategic' review with a reverse merger
A little Norwegian biotech announced the end of its journey Thursday in a reverse merger, roughly three months after announcing it would essentially sell itself for parts.
Nordic Nanovector will be swallowed by another biotech based out of Norway, APIM Therapeutics, the companies said Thursday. When all is said and done, APIM shareholders will own 76% of the combined company, which will unveil a new name at a later date, while Nordic Nanovector shareholders will have 24%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.